To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Investigator
- Kenneth Cusi
- Ages
- 21 Years - 75 Years
- Sexes
- All
Clinical trials
-
NIH AIM 2 - Low Dose Pioglitazone in NASH